MYOMO, INC. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 56/100
What the filing says
Myomo reported Q2 2026 revenue of $11.7M (up 21% YoY), raised full-year guidance from prior range to $45-47M (10-15% growth), and posted Adjusted EBITDA loss of $0.8M vs. $4.0M loss in Q2 2025—a 79% improvement. Key drivers: 53% of Q2 revenue from recurring patient sources (vs. 26% in Q2 2025); in-network access expanded to 100M+ covered lives; gross margin expanded 940 bps to 72.1%; operating expenses held flat despite 21% revenue growth. Cash position: $13.5M (down from $18.4M at year-end); operating cash burn improved to $1.9M in Q2 vs. $8.9M in Q2 2025.
Why this rating
Revenue growth and margin expansion are meaningful for a $62M-cap med-device company; raised guidance signals traction. However, company still unprofitable, cash runway ~2 years at current burn, and 42.7M shares outstanding dilutes EPS. Moderate significance: positive momentum but early-stage profitability path.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.